Abstract
Immunotherapy of pulmonary carcinoma The possibility to use immunotherapy for treatment of bronchogenic carcinoma has been under consideration for many years now. New findings regarding cellular and molecular mechanisms in the immune system have led to renewed interest in this therapeutic modality.
The focus is mainly on inhibition of immune checkpoints using monoclonal antibodies blocking CTLA-4 (cytotoxic T lymphocytic antigen 4) and the PD1 receptor (the programmed cell death protein) and its ligand PD-L1 and the antigen for specific vaccine immunotherapy.